Evidence Hub

S1040 Trends in Proton Pump Inhibitor Utilization and Cost in the United States: A Six-Year Analysis of MEPS Data (2017-2022)

Anirudha Chatterjee, Hari Movva

The American Journal of Gastroenterology, 2025

Abstract

Introduction: Proton pump inhibitors (PPIs) are among the most prescribed medications in the United States. While effective for acid-related disorders, long-term PPI use has raised concerns about overuse, cost, and potential adverse effects. Understanding recent trends in prescribing and cost burden can inform deprescribing efforts and health policy. This study analyzes 6 years of nationally representative data to assess trends in PPI prescription volume, total costs, and out-of-pocket (OOP) expenses. Methods: We analyzed public-use data from the Medical Expenditure Panel Survey (MEPS) for 2017-2022. Prescription-level data were extracted from each year’s prescribed medicines file. Records were filtered for all PPI medications (dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole) using generic and brand names. Total cost was defined using the MEPS-imputed variable summing all payment sources; OOP cost was defined as the amount paid by self or family. For each year, we calculated total prescription counts, average total cost per prescription, and average OOP cost. Results: Between 2017 and 2022, a total of 1,737,845 PPI prescriptions were recorded. Prescription volume peaked in 2018 (319,109) and declined to 232,418 in 2022 (-27.2%). Average total cost per prescription decreased from $86.75 in 2017 to $41.51 in 2022 (-52.2%). OOP costs declined more modestly, from $8.75 to $7.41 (-15.3%). While prescription counts fell after 2021, total…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free